Merck to Acquire CN201, Expanding B-cell Disease Treatment Pipeline
Key Highlights Merck to acquire CN201, a clinical-stage bispecific antibody targeting B-cell diseases. Transaction valued at $700M upfront,…
Browsing Tag
Curon Biopharmaceutical
1 post